首页> 外文期刊>Respiratory Research >GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease
【24h】

GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease

机译:慢性阻塞性肺疾病中的GDF-15血浆水平与亚临床冠状动脉疾病相关

获取原文
           

摘要

BackgroundGrowth differentiation factor-15 (GDF-15), a cytokine associated with cardiovascular mortality, increases during chronic obstructive pulmonary disease (COPD) exacerbations, but any role in stable COPD is unknown. We tested associations between GDF-15 and subclinical coronary atherosclerosis, assessed by coronary artery calcium (CAC) score, in COPD subjects free of clinical cardiovascular disease (CVD). MethodsCross-sectional analysis of COPD participants (GOLD stages 2–4) in the COPDGene cohort without CVD at enrollment, using baseline CAC (from non-EKG-gated chest computed tomography) and plasma GDF-15 (by custom ELISA). We used multinomial logistic modeling of GDF-15 associations with CAC, adjusting for demographics, baseline risk (calculated using the HEART: Personal Heart Early Assessment Risk Tool (Budoff et al. 114:1761-1791, 2006) score), smoking history, measures of airflow obstruction, emphysema and airway disease severity. ResultsAmong 694 participants with COPD (47% women, mean age 63.6?years) mean GDF-15 was 1,304?pg/mL, and mean CAC score was 198. Relative to the lower GDF-15 tertile, higher tertiles showed bivariate association with increasing CAC score (mid tertile odds ratio [OR] 1.80, 95% confidence interval [CI] 1.29, 2.51; higher tertile OR 2.86, CI 2.04, 4.02). This association was maintained after additionally adjusting for baseline CVD risk, for co-morbidities and descriptors of COPD severity and impact, markers of cardiac stress (N-terminal pro–B-type natriuretic peptide, troponin T) and of inflammation (Interleukin-6), and in subgroup analysis excluding men, diabetics, current smokers or those with limited ambulation. ConclusionsIn ever-smokers with COPD free of clinical CVD, GDF-15 contributes independently to subclinical coronary atherosclerosis. Trial registrationClinicalTrials.gov, NCT00608764 . Registered 28 January 2008.
机译:背景生长分化因子15(GDF-15)是一种与心血管疾病死亡率相关的细胞因子,在慢性阻塞性肺疾病(COPD)恶化期间会增加,但在稳定COPD中的任何作用尚不清楚。我们在无临床心血管疾病(CVD)的COPD受试者中测试了GDF-15与亚临床冠状动脉粥样硬化之间的关联,并通过冠状动脉钙(CAC)评分进行了评估。方法使用基线CAC(来自非EKG门控胸部计算机断层扫描)和血浆GDF-15(通过定制ELISA)对入组时无CVD的COPDGene队列中COPD参与者(GOLD 2-4期)进行横断面分析。我们使用GDF-15与CAC关联的多项逻辑模型,调整了人口统计学,基线风险(使用HEART:个人心脏早期评估风险工具(Budoff等人114:1761-1791,2006)评分),吸烟史,气流阻塞,肺气肿和气道疾病严重程度的措施。结果694名COPD参与者(47%的女性,平均年龄63.6岁)平均GDF-15为1,304?pg / mL,平均CAC得分为198。相对于较低的GDF-15三分位数,较高的三分位数与增加的二元相关CAC得分(三分位数优势比[OR] 1.80、95%置信区间[CI] 1.29、2.51;三分位数较高的OR 2.86,CI 2.04、4.02)。在进一步调整了基线CVD风险,COPD的合并症和并发症,COPD严重程度和影响,心脏压力的标志物(N端前B型利尿钠肽,肌钙蛋白T)和炎症的标志物(Interleukin-6)后,这种联系得以维持。 ),并且在亚组分析中不包括男性,糖尿病患者,现时吸烟者或行动不便者。结论在无临床CVD的COPD吸烟者中,GDF-15单独导致亚临床冠状动脉粥样硬化。试用注册ClinicalTrials.gov,NCT00608764。 2008年1月28日注册。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号